Andrew Baum
Stock Analyst at Citigroup
(2.89)
# 1,346
Out of 5,182 analysts
67
Total ratings
76.74%
Success rate
15%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $53 → $60 | $58.04 | +3.38% | 15 | Jan 27, 2026 | |
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $27.25 | -4.59% | 11 | Aug 6, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $116.39 | -1.19% | 13 | Feb 5, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $48.39 | -17.33% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $208.38 | +3.18% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $906.74 | -1.29% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $3.62 | +176.24% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $57.34 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Jan 27, 2026
Maintains: Neutral
Price Target: $53 → $60
Current: $58.04
Upside: +3.38%
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $27.25
Upside: -4.59%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $116.39
Upside: -1.19%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $48.39
Upside: -17.33%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $208.38
Upside: +3.18%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $906.74
Upside: -1.29%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $3.62
Upside: +176.24%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $57.34
Upside: -